Search Results

The NovoPen Echo® is a re-useable pen injector designed for single patient use by diabetics for the self-injection of a desired dose of insulin. The pen injector uses PenFill® 3 mL cartridge of NovoLog®, 100 units/mL (U-100) [insulin aspart injection], Fiasp® 100 units/mL (U-100) [insulin aspart injection], and a single use detachable and disposable pen needle (supplied separately). The pen injector allows the user to dial the desired dose from 0.5 to 30 units in 0.5 unit increments.

The NovoPen Echo® is a reusable mechanical pen-injector capable of injecting a dose of up to 30 units of insulin, in 0.5 unit increments, from a NovoLog 3 mL PenFill® cartridge. The memory function enables the user of the device to see the quantity of last given dose and hours that have passed since last dose. The operation of the pen-injection of insulin is entirely independent of the operation of the memory function. The intended dose is mechanically set by rotating a dose button. The insulin is injected by depressing the dose button which via mechanical coupling causes the piston in the insulin cartridge to move forward thereby expelling the intended dose. The device has a memory function and liquid crystal display that allows the user to review the units of the last dose and the number of hours that have elapsed since the last dose was taken. Rotation of the dose button during dose setting causes a sensor to rotate within a coded cylinder. The movement detected by this sensor is stored for later display on the liquid crystal display in the dosage selector module as the number of units injected.

The provided text describes a 510(k) premarket notification for the NovoPen Echo®, specifically to expand its approved use to include Fiasp® (insulin aspart injection) 3mL PenFill® cartridges. It primarily focuses on demonstrating substantial equivalence to a previously cleared device (K162602) rather than presenting a standalone study of the device's diagnostic or therapeutic performance in a clinical setting.

Therefore, many of the requested categories for acceptance criteria and study details are not directly applicable or available in this regulatory document. This document is about a device's safety and performance in delivering a drug, not about its diagnostic accuracy or establishing a new therapeutic effect.

Here's the information that can be extracted or reasonably inferred from the document:

1. A table of acceptance criteria and the reported device performance

2. Sample size used for the test set and the data provenance

• Sample Size: Not explicitly stated for the dose accuracy performance test. ISO11608-1:2014 would specify the number of individual tests (e.g., number of pens tested, number of doses per pen) required for compliance. This document only states that the testing was performed and met the standard.
• Data Provenance: Not specified, but generally, such performance tests are conducted by the manufacturer (Novo Nordisk) in a controlled laboratory environment. It is not clinical data, so terms like "retrospective or prospective" or "country of origin of the data" are not applicable in this context.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

• This is not applicable. The "ground truth" for a mechanical device's dose accuracy is typically established by precision measurement equipment (e.g., gravimetric or volumetric methods) in an engineering or metrology lab, not by human experts, and certainly not by medical experts for diagnostic purposes.

4. Adjudication method (e.g., 2+1, 3+1, none) for the test set

• Not applicable. This concept applies to human interpretation of diagnostic data where a consensus among experts is needed. For mechanical performance testing, the results are objectively measured.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

• Not applicable. This is a medical device for insulin delivery, not an AI-assisted diagnostic tool or a system involving human readers/interpreters in a diagnostic context.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

• Not applicable in the sense of an algorithm for diagnosis or interpretation. The device itself operates mechanically. The "standalone" performance here refers to the device's ability to accurately deliver insulin doses, which was tested.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

• The "ground truth" for device performance (dose accuracy) would be the precisely measured volume or weight of liquid dispensed, determined using calibrated laboratory equipment according to the methods outlined in ISO11608-1:2014.

8. The sample size for the training set

• Not applicable. The NovoPen Echo® is a mechanical device, not an AI/ML algorithm that requires training data.

9. How the ground truth for the training set was established

• Not applicable for the reason above.

Ask a specific question about this device

The NovoPen Echo® is a re-useable pen injector designed for single patient use by diabetics for the seff-injection of a desired dose of insulin. The pen injector uses PenFill® 3 mL cartridge of NovoLog®, 100 units/mL (U-100) [insulin aspart (rDNA origin) injection] and a single use detachable and disposable pen needle (supplied separately). The pen injector allows the user to dial the desired dose from 0.5 to 30 units in 0.5 unit increments.

The NovoPen Echo® is a reusable mechanical pen-injector capable of injecting a dose of up to 30 units of insulin, in 0.5 unit increments, from a NovoLog 3 mL PenFill® cartridge. The memory function enables the user of the device to see the quantity of last given dose and hours that have passed since last dose. The operation of the pen-injection of insulin is entirely independent of the operation of the memory function. The intended dose is mechanically set by rotating a dose button. The insulin is injected by depressing the dose button which via mechanical coupling causes the piston in the insulin cartridge to move forward thereby expelling the intended dose. The device has a memory function and liquid crystal display that allows the user to review the units of the last dose and the number of hours that have elapsed since the last dose was taken. Rotation of the dose button during dose setting causes a sensor to rotate within a coded cylinder. The movement detected by this sensor is stored for later display on the liquid crystal display in the dosage selector module as the number of units injected.

The provided document is a 510(k) Special Summary for the NovoPen Echo®, a reusable pen injector for insulin. It describes the device, its intended use, and the rationale for claiming substantial equivalence to predicate devices.

However, the document does not contain information about an AI/Algorithm-based diagnostic or prognostic device. Therefore, it is not possible to extract the requested information regarding acceptance criteria, study details (test set, ground truth experts, adjudication, MRMC, standalone performance), or training set specifics as this type of information is not relevant to the described device.

The document states:

• "No clinical testing was provided or required." (Page 5)
• The performance testing was device verification tests to ensure compliance with ISO11608-1 "Needle-based injection systems for medical use - Requirements and test methods - Part 1: Needle-based injection systems." (Page 4)

Therefore, the requested details about an AI study (sample sizes, expert consensus, MRMC, training sets) are not applicable to the content of this 510(k) submission.

Ask a specific question about this device

The NovoPen Echo® is a re-useable pen injector designed for single patient use by diabetics for the self-injection of a desired dose of insulin. The pen injector uses PenFill® 3 mL cartridge of NovoLog®, 100 units/mL (U-100) finsulin aspart (rDNA origin) injection] and a single use detachable and disposable pen needle (supplied separately). The pen injector allows the user to dial the desired dose from 0.5 to 30 units in 0.5 unit increments.

The NovoPen Echo® (STJ) is a reusable mechanical pen-injector capable of injecting a dose of up to 30 units of insulin, in 0.5 unit increments, from a PenFill® 3 mL cartridge of NovoLog®, 100 units/mL (U-100) [Insulin aspart Injection (rDNA origin)] . The memory function enables the user of the device to see the quantity of last given dose and hours that have passed since last dose. The operation of the pen-injector for the injection of insulin is entirely independent of the operation of the memory function. The intended dose is mechanically set by rotating a dose button. The insulin is injected by depressing the dose button which via mechanical coupling causes the piston in the insulin cartridge to move forward thereby expelling the intended dose. The device has a memory function and liquid crystal display that allows the user to review the units of the last dose and the number of hours that have elapsed since the last dose was taken. Rotation of the dose button during dose setting causes a sensor to rotate within a coded cylinder. The movement detected by this sensor is stored for later display on the liquid crystal display in the dosage selector module as the number of units injected. The pen-injector is intended for use with PenFill® 3 mL cartridge of NovoLog", 100 units/mL (U-100) [Insulin aspart Injection (rDNA origin)] and a single-use, detachable and disposable pen needle (supplied separately by Novo Nordisk ).

The provided document is a 510(k) summary for the NovoPen Echo® device, specifically for a change in manufacturing location and minor updates to the device. It focuses on demonstrating substantial equivalence to a previously cleared predicate device, rather than presenting a de novo study with novel acceptance criteria and reported device performance from a new efficacy trial.

Therefore, the document does not contain the detailed information necessary to fully address all points concerning acceptance criteria and study design as typically expected for a new device's efficacy study.

However, based on the available information, here's what can be extracted and inferred:

1. A table of acceptance criteria and the reported device performance

The document states that the device was evaluated against the requirements specified in ISO 11608-1:2012 Needle-based injection systems for medical use - Requirements and test methods - Part 1: Needle-based injection systems. This standard would define the acceptance criteria for performance aspects such as dosing accuracy, dose button force, and other functional parameters relevant to pen injectors.

While specific numerical acceptance criteria and reported performance values are not provided in this summary, the document states:

• "Device Verification Tests were run to verify all product requirements are still met and all changes work properly and complies with the requirements specified in ISO11608-1:2012"
• "Software verification and validation regression testing all static, unit, integration and system, tests as well as additional tests for the changes and related risk control measures was conducted and all tests passed."
• "In conclusion, the results of the testing demonstrate that NovoPen Echo® (STJ) is as safe and effective and performs as well as the predicate device."
• "The results of the testing to standards provide additional evidence that NovoPen Echo® (STJ) is substantially equivalent to the predicate device, NovoPen Echo® (DMD)."

Therefore, the implied acceptance criteria are compliance with ISO 11608-1:2012 and the reported device performance is that it met all product requirements and passed all tests, demonstrating substantial equivalence to the predicate device.

Without the full test reports, a detailed table with specific numerical criteria and results cannot be generated from this summary.

2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

• Sample Size: Not specified in the summary.
• Data Provenance: The tests were conducted to support the transfer of manufacturing from Denmark (DMD) to Tianjin, China (STJ), implying the testing was performed on devices produced at the new manufacturing site. The study is prospective in the sense that newly manufactured devices were tested to confirm performance.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This type of information is not applicable to the type of device (pen injector) and the nature of this submission (manufacturing change). Ground truth for a pen injector's functional performance would typically be established through engineering measurements and adherence to international standards, not through expert consensus on diagnostic images or similar expert review processes.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Not applicable for this type of device and submission. Adjudication methods are typically used in studies involving subjective interpretation (e.g., medical imaging) to resolve disagreements among human readers.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. The NovoPen Echo® is a mechanical pen injector designed for patient self-injection, not an AI-powered diagnostic or assistive tool for human readers.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

This question is typically relevant for AI/software devices. The NovoPen Echo® is a mechanical device with a memory function and liquid crystal display; its "memory function" is described as a sensor detecting movement for display, not a complex algorithm performing diagnosis or analysis. The performance verified was related to the mechanical and display functionalities, meaning a form of "standalone" evaluation of the device's technical specifications was performed according to ISO standards.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

The "ground truth" for the device's performance is objective measurement against the specifications and requirements outlined in ISO 11608-1:2012 and potentially internal product requirements for dose accuracy, delivery force, functionality of the display, etc. This is based on engineering and physical measurement standards, not expert consensus, pathology, or outcomes data.

8. The sample size for the training set

Not applicable. This device is not an AI-driven learning algorithm that requires a training set.

9. How the ground truth for the training set was established

Not applicable (as per point 8).

Ask a specific question about this device

The NovoPen Echo* is a re-useable pen injector designed for single patient use by diabetics for the self-injection of a desired dose of insulin. The pen injector uses Penli ill " 3 mL cartridges of Novo Nordisk insulin and a single use detachable and disposable pen needle (supplied separately). The pen injector allows the user to dial the desired dose from 0.5 to 30 units in one-half (1/2) unit increments.

The NovoPen Echo® is a reusable mechanical pen-injector capable of injecting a dose of up to 30 units of insulin, in half unit increments, from a Novo Nordisk 3.0 mL insulin cartridge. The intended dose is mechanically set by rotating a dose button. The insulin is injected by depressing the dose button which via mechanical coupling causes the piston in the insulin cartridge to move forward thereby expelling the intended dose. The device has a memory function and liquid crystal display that allows the user to review the units of the last dose and the number of hours that have elapsed since the last dose was taken. Rotation of the dose button during dose setting causes a sensor to rotate within a coded cylinder. The movement detected by this sensor is stored for later display on the liquid crystal display in the dosage selector module as the number of units injected. The pen-injector is intended for use with Novo Nordisk 3.0 mL insulin cartridges and single-use, detachable and disposable pen needle (supplied separately by Novo Nordisk).

The provided text describes the NovoPen Echo® insulin delivery device and its 510(k) summary. However, it does not contain the detailed acceptance criteria and study information as requested. The document states that the device meets design requirements and complies with ISO 11608-1, and that Human Factor testing documented its safety. It also mentions a shelf life.

Here's a breakdown of what is present and what is missing from your request:

What is present (to a limited extent):

• Acceptance Criteria Mention: The document states that "The results of design verification testing has documented that the NovoPen Echo® meets all its design requirements and complies with the requirements specified in ISO 11608-1 Pen-injectors for medical use - Part 1: Pen-injectors - Requirements and test methods." This implies that the acceptance criteria are based on ISO 11608-1, but the specific numerical criteria or performance targets are not listed. It also mentions that "Human Factor testing has documented that the NovoPen Echo" is safe to use."
• Study Mention: "Design verification testing" and "Human Factor testing" are mentioned as studies performed.
• Device Performance Mention: It states the device "meets all its design requirements and complies with the requirements specified in ISO 11608-1" and "is safe to use." Specific performance metrics are not given.

What is largely missing from the provided text:

1. A table of acceptance criteria and the reported device performance: The text mentions meeting ISO 11608-1, but doesn't detail the requirements from that standard or the specific performance results in a table format.
2. Sample size used for the test set and the data provenance: Not mentioned.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not applicable as no specific "test set" or "ground truth" derived from experts for performance metrics is detailed. The human factors testing likely involved users, but specifics are absent.
4. Adjudication method for the test set: Not applicable.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, and its effect size: Not applicable as this is a medical device (insulin pen), not an AI diagnostic tool.
6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done: Not applicable as this is a physical medical device.
7. The type of ground truth used: Not applicable for device performance in the context of ISO standards. For human factors, "safety" is the ground truth, assessed by user interaction.
8. The sample size for the training set: Not applicable for a mechanical device.
9. How the ground truth for the training set was established: Not applicable for a mechanical device.

Table of Acceptance Criteria and Reported Device Performance (Based only on the provided text, heavily inferred):

In summary, the provided 510(k) summary is a high-level document confirming that testing was done and the device met requirements set by an international standard (ISO 11608-1) and human factors principles. It does not elaborate on the specific details of those tests, such as sample sizes, ground truth establishment methods, or the specific numerical performance results.

Ask a specific question about this device